Prostate cancer responds well to androgen depletion therapy(ADT).
However, when ADT was initiated on advanced prostate cancer, many become Castration-Resistant Prostate Cancer(CRPC)within a few years. Thus, development of new agents against CRPC is warranted. At the 2012 ASCO Meeting, results from two global randomized trials were given a warm reception. One trial involved abiraterone acetate and the other MDV3100.
Written by:
Akaza H. Are you the author?
Dept. of Strategic Investigation on Comprehensive Cancer Network, University of Tokyo, Tokyo, Japan.
Reference: Gan To Kagaku Ryoho. 2013 Jan;40(1):30-4.
PubMed Abstract
PMID: 23306917
Article in Japanese.
